Retinoids in the chemoprevention of bladder cancer

Current Opinion in Oncology

Volumn 10, Issue 5, 1998, Pages 479-484

  Sabichi, Anita L ^a   Lerner, Seth P ^b   Grossman, H Barton ^c   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE; FENRETINIDE; ISOTRETINOIN; RETINOID;

APOPTOSIS; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CANCER INVASION; CYSTECTOMY; CYSTOSCOPY; HUMAN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; SUPERFICIAL CANCER; TOBACCO; UNITED STATES;

EID: 14444277709     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199809000-00019     Document Type: Short Survey

References (33)

1. Landis SH, Murray T, Bolden S, Wingo P: Cancer Statistics, 1998. CA Cancer J Clin 1998, 48:6-9.
2. Fradet Y: Epidemiology of bladder cancer. In Comprehensive Textbook of Genitourinary Oncology. Edited by Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, Baltimore, MD: Williams and Wilkins; 1996:298-304.
3. Reading J, Hall RR, Parmar MKB: The application of a prognostic factor analysis for TaT1 bladder cancer in routine urological practice. Br J Urol 1995, 75:604-607.
4. Morgan JDT, Bowsher W, Griffiths DFR, Matthews PN: Rationalization of follow-up in patients with non-invasive bladder tumors. Br J Urol 1991, 67:158-161.
5. Trump DL: Retinoids in bladder, testis and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 1994, 8:S50-S54. This review covers in vitro studies, preclinical in vivo studies, and clinical studies involving retinoids in urologie tumors including bladder, testis, and prostate cancers.
6. Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B: Clonal origin of bladder cancer. N Engl J Med 1992, 326:737-740. This extremely important paper includes clonal analysis of a range of stage and grade of bladder tumors analyzed for allelic loss of heterozygosity for a number of chromosomal markers in bladder cancer and analysis of chromosome X. The results provide strong evidence that multifocal bladder tumors can arise from a single progenitor cell, and subsequently undergo further alterations during development of each individual tumor.
7. Grossman HB: Superficial bladder cancer: Decreasing the risk of recurrence. Oncology 1996, 10:1617-1624. This well-referenced review thoroughly discusses superficial bladder cancer biology and current therapies, including surgical and intravesical chemotherapy. The recurrence rates for these therapies are compared. New therapeutic strategies including immunomodulators (eg, interferon alfa, interleukin-2, and tumor necrosis factor) and other new treatment strategies are reviewed.
8. Grossman HB, Liebert M, Antelo M, Dinney CPN, Hu S-X, Palmer JL, Benedict WF: p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998, 4:829-834. Tumor suppressor genes p53 and RB were evaluated as potential prognostic markers for progression in a cohort of 45 patients with pT1 bladder cancer. In patients who did not have early cystectomy, progression-free survival (median follow-up, 3.75 years) was highly significantly correlated with expression of each protein (wild-type p53 and RB, best survival; both proteins altered, worst survival; either p53 or RB altered, intermediate survival). These findings suggest that alterations in these genes contribute to the invasive potential of tumors; therefore such markers can be used to identify high-risk patients.
9. Ross RK, Jones PA, Yu MC: Bladder Cancer Epidemiology and Pathogenesis. Semin Oncol 1996, 23:536-545.
10. Mayne ST, Lippman SM: Retinoids and carotenoids. In Cancer: Principles and Practice of Oncology, edn 5. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven; 1997:585-599.
11. Sporn MB, Squire RA, Brown CC, Smith JM, Wenk ML, Springer S: 13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 1977, 195:487-489.
12. Moon RC, Detrisac CJ, Thomas CF, Kelloff GJ: Chemoprevention of experimental bladder cancer. J Cell Biochem 1992, 161:134-138.
13. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 1996, 10:940-954. This paper reviews the important role that retinoids and retinoid receptors play during vertebrate development, and in cellular differentiation and homeostasis with focus on recent developments in retinoid biology. The authors discuss the effects that underlie the diversity in control of gene expression by retinoid signals generated through different levels of the retinoid signaling pathway and complex mechanisms of cross-modulation of the signaling pathways generated by these ligand-activated receptors.
14. Lotan R, Xu X-C, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK: Suppression of retinoic acid receptor-β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 1995, 332:1405-1410.
15. Moon RC, Mehta RG, Rao KV: Retinoids and cancer in experimental animals. In The Retinoids, edn 2. Edited by Sporn MD, Roberts AB, Goodman DS. New York: Raven Press; 1994:573-596.
16. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, et al.: Clinical development plan: N-(4-hydroxyphenyl) retinamide (4HPR). J Cell Biochem (Suppl) 1994, 20:176-196.
17. Naik HR, Kalemkerian G, Pienta KJ: 4-Hydroxyphenylretinamide in the Chemoprevention of cancer. Adv Pharmacol 1995, 33:315-347. Comprehensive review with 98 references of the safety and efficacy of the synthetic retinide fenretinide in preclinical and human Chemoprevention trials.
18. Zou CP, Zou CC, Lippman SM, Lotan R: Identification of synthetic retinoids that are potent inducers of apoptosis in bladder cancer cells [abstract]. Proc Am Assoc Cancer Res 1998, 39:359.
19. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ: Retinoic acid receptor-β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hyroxyphenyl) retinamide. J Natl Cancer Inst 1998, 90:597-605. Addresses a mechanism of the synthetic retinide fenretinide in gynecologic cancer cell lines. Fenretinide inhibited the in vitro proliferation of 12 gynecologic cancer cells to varying degrees. The authors found an association between the expression of specific retinoid receptors and the degree of sensitivity of the various cell lines to the retinoid. Ovarian cancer cells engineered to express high levels of RAR-β were particularly sensitive to fenretinide. These findings suggest that sensitivity to fenretinide may be modulated by the retinoic acid receptor-β in these cell lines.
20. Pollard M, Luckert PH, Sporn MB: Prevention and primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991, 51:3610-3611.
21. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993, 53:224-226.
22. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Ruffaghello L, et al.: Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995, 55:853-861.
23. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, et al.: N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993, 53:6036-6041.
24. Kalemkerian GP, Slusher R, Sakkaraiappan R, Gadgeel S, Mabry M: Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 1995, 87:1674-1680.
25. Oridate N, Lotan D, Xu X-C, Hong WK, Lotan R: Induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 1996, 2:855-863.
26. Park JR, Robertson K, Hickstein DD, Tsai S, Hackenberg DM, Collins SJ: Dysregulated Bcl 2 expression inhibits apoptosis but not differentiation of retinoic acid-induced HL-60 granulocytes. Blood 1994, 84:440-445.
27. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, et al.: Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregualted bcl-2. Blood 1995, 85:359-367.
28. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R: Involvement of reactive oxygen species in N-(hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997, 89:1191-1198. Addresses a mechanism of action of fenretinide in inhibition of growth of cervical carcinoma cell line C334. Treatment of these cells with fenretinide resulted in apoptosis and an associated enhanced generation of reactive oxygen species. Both of these effects could be suppressed by addition of an oxygen radical scavenger. These findings suggest that generation of reactive oxygen species may be inportant mechanism for fenretinide, because reactive oxygen species have been shown to be involved in the apoptotic pathway induction by fenretinide.
29. Decensi A, Costa A, De Palo G, Formelli F, Marubini E, Mariani E, Mariani L, Fontana V, Veronesi U: Retinoid-menopause interactions in a breast cancer prevention trial [abstract]. Proc Am Assoc Cancer Res 1997, 38:529.
30. De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, et al.: Can fenretinide protect women against ovarian cancer? J Natl Cancer lnst 1995, 87:146-147.
31. Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, et al.: Fenretinida (4HPR) in chemoprevention of oral leukoplakia. J Cell Biochem (Suppl) 1993, 17F:255-261.
32. Decensi A, Bruno S, Costantini M, Torrisi R, Curotto A, Gatteschi B, et al.: Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate endpoint. J Natl Cancer Inst 1994, 86:138-140.
33. Decensi A, Torrisi R, Bruno S, Curotto A, Malcangi B, Nicolo G, Bruttini GP, Costantini M, Rondanina G, Baglietto L, et al.: Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint [abstract]. Proc Am Soc Clin Oncol 1997, 16:541a.